Meanwhile, there are multiple therapeutic options in which tyrosine kinase inhibitors (TKIs) are first-line choice in therapy or co-therapy, i.e. targeting epidermal growth factor receptor (EGFR) subtypes using erlotinib or gefitinib in HER1-overexpressing tumors, as well as lapatinib to inhibit HER2 in HER2-positive breast cancer, targeting angiogenesis via vascular endothelial growth factor receptor VEGF(R) inhibition or blockade of kinases, such as c-kit (CD117), platelet derived growth factor receptor (PDGFR), or anaplastic lymphoma kinase (ALK), just to name a few (Jiao et al., 2018). This evidence concerns the gene ALK and breast cancer.